Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts

Cell Reports

Volumn 16, Issue 6, 2016, Pages 1701-1716

  Ngo, Michael ^a   Han, Arum ^a   Lakatos, Anita ^a   Sahoo, Debashis ^b   Hachey, Stephanie J ^a   Weiskopf, Kipp ^c   Beck, Andrew H ^d   Weissman, Irving L ^c   Boiko, Alexander D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUROTROPHIN RECEPTOR P75; PROTEIN ANTIBODY; PROTEIN TYROSINE PHOSPHATASE SHP; THROMBOSPONDIN 1; ADAPALENE; CD47 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOPHENOTYPING; INNATE IMMUNITY; MELANOMA; METASTATIC MELANOMA; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; TUMOR XENOGRAFT; UPREGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ADAPALENE; CD47 ANTIGEN; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; MACROPHAGES; MELANOMA; NEOPLASM METASTASIS; PHAGOCYTOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84979781372     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.07.004     Document Type: Article

References (55)

1. 2-dependent pathways. Mol. Cell. Biol. 25 (2005), 7181–7192.
2. American Cancer Society (2015). American Cancer Society Cancer Facts & Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
3. Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11 (2010), 889–896.
4. Boiko, A.D., Razorenova, O.V., van de Rijn, M., Swetter, S.M., Johnson, D.L., Ly, D.P., Butler, P.D., Yang, G.P., Joshua, B., Kaplan, M.J., et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466 (2010), 133–137.
5. Boiko, A.D., Isolation of melanoma tumor-initiating cells from surgical tissues. Methods Mol Biol 961 (2013), 253–259.
6. Callahan, M.K., Postow, M.A., Wolchok, J.D., CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front. Oncol., 4, 2015, 385.
7. Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., Jan, M., Cha, A.C., Chan, C.K., Tan, B.T., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142 (2010), 699–713.
8. Chao, M.P., Weissman, I.L., Majeti, R., The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24 (2012), 225–232.
9. Civenni, G., Walter, A., Kobert, N., Mihic-Probst, D., Zipser, M., Belloni, B., Seifert, B., Moch, H., Dummer, R., van den Broek, M., Sommer, L., Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71 (2011), 3098–3109.
10. Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., Ferri, L., Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. 123 (2013), 3446–3458.
11. Cormier, J.N., Salgaller, M.L., Prevette, T., Barracchini, K.C., Rivoltini, L., Restifo, N.P., Rosenberg, S.A., Marincola, F.M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3 (1997), 37–44.
12. Dudley, M.E., Wunderlich, J., Nishimura, M.I., Yu, D., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Sherry, R., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 24 (2001), 363–373.
13. Edris, B., Weiskopf, K., Volkmer, A.K., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R.B., Fletcher, J.A., et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. USA 109 (2012), 6656–6661.
14. Fine, A., Hoyle, C., Maclean, C.J., Levatte, T.L., Baker, H.F., Ridley, R.M., Learning impairments following injection of a selective cholinergic immunotoxin, ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys. Neuroscience 81 (1997), 331–343.
15. Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., Pamer, E.G., Li, M.O., The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925.
16. Fridlender, Z.G., Albelda, S.M., Tumor-associated neutrophils: friend or foe?. Carcinogenesis 33 (2012), 949–955.
17. Ginhoux, F., Jung, S., Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14 (2014), 392–404.
18. Guo, R., Fierro-Fine, A., Goddard, L., Russell, M., Chen, J., Liu, C.Z., Fung, K.M., Hassell, L.A., Increased expression of melanoma stem cell marker CD271 in metastatic melanoma to the brain. Int. J. Clin. Exp. Pathol. 7 (2014), 8947–8951.
19. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
20. Hoeffel, G., Wang, Y., Greter, M., See, P., Teo, P., Malleret, B., Leboeuf, M., Low, D., Oller, G., Almeida, F., et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J Exp Med 209 (2012), 1167–1181.
21. Isenberg, J.S., Ridnour, L.A., Dimitry, J., Frazier, W.A., Wink, D.A., Roberts, D.D., CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J. Biol. Chem. 281 (2006), 26069–26080.
22. Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver, D., van Rooijen, N., Weissman, I.L., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138 (2009), 271–285.
23. Johansson, U., Higginbottom, K., Londei, M., CD47 ligation induces a rapid caspase-independent apoptosis-like cell death in human monocytes and dendritic cells. Scand. J. Immunol. 59 (2004), 40–49.
24. Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001), 402–408.
25. Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D. Jr., van Rooijen, N., Weissman, I.L., CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138 (2009), 286–299.
26. Manna, P.P., Frazier, W.A., CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res. 64 (2004), 1026–1036.
27. Marchetti, D., Menter, D., Jin, L., Nakajima, M., Nicolson, G.L., Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production. Int. J. Cancer 55 (1993), 692–699.
28. Marchetti, D., Aucoin, R., Blust, J., Murry, B., Greiter-Wilke, A., p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J Cell Biochem. 91 (2004), 206–215.
29. Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep., 6, 2014, 13.
30. Mateo, V., Lagneaux, L., Bron, D., Biron, G., Armant, M., Delespesse, G., Sarfati, M., CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat. Med. 5 (1999), 1277–1284.
31. Mawby, W.J., Holmes, C.H., Anstee, D.J., Spring, F.A., Tanner, M.J., Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem. J. 304 (1994), 525–530.
32. Maxhimer, J.B., Soto-Pantoja, D.R., Ridnour, L.A., Shih, H.B., Degraff, W.G., Tsokos, M., Wink, D.A., Isenberg, J.S., Roberts, D.D., Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci. Transl. Med., 1, 2009, 3ra7.
33. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
34. Murdoch, C., Muthana, M., Coffelt, S.B., Lewis, C.E., The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8 (2008), 618–631.
35. Okazawa, H., Motegi, S., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y., Oldenborg, P.A., Ishikawa, O., Matozaki, T., Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol. 174 (2005), 2004–2011.
36. O'Neil, B.H., Kawakami, Y., Restifo, N.P., Bennink, J.R., Yewdell, J.W., Rosenberg, S.A., Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol. 151 (1993), 1410–1418.
37. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (2015), 2006–2017.
38. Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51.
39. Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser, E.A., Snyder, L.A., Pollard, J.W., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475 (2011), 222–225.
40. Redmer, T., Welte, Y., Behrens, D., Fichtner, I., Przybilla, D., Wruck, W., Yaspo, M.L., Lehrach, H., Schäfer, R., Regenbrecht, C.R., The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS ONE, 9, 2014, e92596.
41. Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.R., Roberts, A.I., Zhang, L., Zheng, B., et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell 11 (2012), 812–824.
42. Ribas, A., Shin, D.S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol. Res. 4 (2016), 194–203.
43. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2015), 320–330.
44. Roszer, T., Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm., 2015, 2015, 816460.
45. Sarraf, K.M., Belcher, E., Raevsky, E., Nicholson, A.G., Goldstraw, P., Lim, E., Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 137 (2009), 425–428.
46. Saumet, A., Slimane, M.B., Lanotte, M., Lawler, J., Dubernard, V., Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood 106 (2005), 658–667.
47. Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M., Wolchok, J.D., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33 (2015), 1889–1894.
48. Serbina, N.V., Pamer, E.G., Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 7 (2006), 311–317.
49. Sheng, J., Ruedl, C., Karjalainen, K., Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity 43 (2015), 382–393.
50. Vernon-Wilson, E.F., Kee, W.J., Willis, A.C., Barclay, A.N., Simmons, D.L., Brown, M.H., CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur. J. Immunol. 30 (2000), 2130–2137.
51. Walsh, S.R., Cook, E.J., Goulder, F., Justin, T.A., Keeling, N.J., Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 91 (2005), 181–184.
52. Wang, Y., Xu, Z., Guo, S., Zhang, L., Sharma, A., Robertson, G.P., Huang, L., Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol. Ther. 21 (2013), 1919–1929.
53. Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J.D., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109 (2012), 6662–6667.
54. Xu, L., Shen, S.S., Hoshida, Y., Subramanian, A., Ross, K., Brunet, J.P., Wagner, S.N., Ramaswamy, S., Mesirov, J.P., Hynes, R.O., Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol. Cancer Res. 6 (2008), 760–769.
55. Zikich, D., Schachter, J., Besser, M.J., Immunotherapy for the management of advanced melanoma: the next steps. Am. J. Clin. Dermatol. 14 (2013), 261–272.